Literature DB >> 1483639

Basing prescription drug payment on economic analysis: the case of Australia.

M F Drummond1.   

Abstract

Mesh:

Year:  1992        PMID: 1483639     DOI: 10.1377/hlthaff.11.4.191

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


× No keyword cloud information.
  8 in total

Review 1.  Quality use of medicines in the community: the Australian experience.

Authors:  A J Smith; P McGettigan
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  Balancing costs, efficacy, and side effects.

Authors:  J Avorn
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Cost-effectiveness guidelines. The experience of Australian manufacturers.

Authors:  P Gorham
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

4.  The emerging government requirement for economic evaluation of pharmaceuticals.

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 5.  The concept of essential medicines: lessons for rich countries.

Authors:  Hans V Hogerzeil
Journal:  BMJ       Date:  2004-11-13

6.  Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.

Authors:  W E Smalley; M R Griffin; R L Fought; W A Ray
Journal:  J Gen Intern Med       Date:  1996-08       Impact factor: 5.128

7.  Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia.

Authors:  D L O'Connell; D Henry; R Tomlins
Journal:  BMJ       Date:  1999-02-20

8.  How do government health departments in Australia access health economics advice to inform decisions for health? A survey.

Authors:  Lynne Madden; Lesley King; Alan Shiell
Journal:  Aust New Zealand Health Policy       Date:  2009-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.